Rakesh Dixit
President & Chief Executive Officer Bionavigen
Rakesh Dixit is a seasoned biotechnology executive and scientific leader with extensive experience in biologics, drug development, and translational sciences. He currently serves as Chief Scientific Officer at TMAB Therapeutics and co-founder, President, and CSO of Regio Biosciences, an AstraZeneca spin-off focused on innovative therapies targeting cardio-metabolic diseases and cancer. He is also President and CEO of Bionavigen, a consultancy specializing in biologics and advanced therapeutics. Previously, he held senior leadership roles at MedImmune and AstraZeneca, overseeing global biologics safety assessment. Dr. Dixit earned his Ph.D. in Toxicology from Case Western Reserve University School of Medicine.
Seminars
- Traditional nonclinical models often fail to predict clinical outcomes for complex ADCs, creating a need for more advanced and biologically relevant preclinical approaches.
- Novel in vitro systems can improve decision-making in drug discovery by providing better insights into key factors such as target uptake, payload characteristics, and tissue toxicity
- Integrating these systems into a broader translational strategy, along with improved species selection, biomarker use, and mechanistic data, can produce more predictive nonclinical packages and enable faster, more confident go/no-go decisions
